Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

38.36 +0.34 (+0.89%)
Official Closing Price Updated: 7:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Here Are All The Corporate CEOs Who Made A Beeline To China To Chase Huge Market Opportunities Amid The Country's Reopening
 
Via Benzinga
3 Dividend Stocks You Can Buy Without Any Hesitation
The choices are easy with these stocks. 
Via The Motley Fool
Why Shares of BioNTech Rose Friday
The company released positive trial data for a non-small cell lung cancer therapy. 
Via The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Why Pfizer Stock Is Perking Up Today
Bargain hunters appear to be circling back to the beaten-down pharma stock today. 
Via The Motley Fool
2 Ultra-Safe Dividend Stocks to Load Up On Right Now
These two beaten-down dividend stocks ought to shine over the long term. 
Via The Motley Fool
Pfizer Unusual Options Activity For May 30
 
Via Benzinga
BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment
BioNTech is testing out a next-generation form of Yervoy, hoping to reduce side effects. 
Via Investor's Business Daily
3 Undervalued Biotech Stocks to Buy Before They Blast Off
Fundamental analysis makes these three undervalued biotech stocks to buy plus they have other catalysts that make them compelling. 
Via InvestorPlace
7 Deeply Undervalued Growth Stocks to Buy in June
Investors may see significant rewards betting on these best undervalued growth stocks for June. 
Via InvestorPlace
AI, Tech Fuel Rebound Of Vanguard Growth ETF, Eroding Value's 2022 Outperformance
The surge of artificial intelligence (AI), the supremacy of the internet giants and expectations of the Fed's tightening cycle nearing its end are propelling growth companies to outperform value... 
Via Benzinga
Pfizer Inc. (NYSE: PFE) Near Top of Volume Charts in Tuesday Trading
Via Investor Brand Network
One man’s journey with advanced prostate cancer
(BPT) - This content is sponsored and provided by Myovant Sciences and Pfizer Inc. 
Via Brandpoint
How Pfizer's First-Ever Approach In Hemophilia Treatment Paid Off
Pfizer hopes to gain approval for the first-ever fixed dose hemophilia drug. 
Via Investor's Business Daily
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Shares surged into and out of the company's R&D Day, which included a surprise. 
Via Investor's Business Daily
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
From Pfizer Inc.
Via Business Wire
Is CXApp Inc.an AI Contender or Pretender?
CXApp Inc. (NASDAQ: CXAI) shares have been caught up in the artificial intelligence (AI) mania. On no news, its shares spiked to $21 on April 23, 2023, and have 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?
Last year, Pfizer reported record revenue. 
Via The Motley Fool
5 Value Stocks In The Healthcare Sector
 
Via Benzinga
Have $2,000? 2 Remarkable Growth Stocks to Buy Right Now
These healthcare giants aren't close to being done growing yet. 
Via The Motley Fool
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
From Pfizer Inc.
Via Business Wire
This Cannabis-Based Drug Has Outperformed Pfizer's Lyrica In Clinical Trials: A New Dawn For Diabetic Nerve Pain Management?
Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a leading player in cannabinoid medicine research, has successfully demonstrated that its proprietary drug for diabetic nerve pain, ZLT-L-007,... 
Via Benzinga
Most Active Equity Options For Midday - Wednesday, May 31
Here are the most active equity options for midday. 
Via Talk Markets
Does Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?
A highly lucrative weight-loss market could be the growth opportunity Pfizer needs to make the stock a better buy. 
Via The Motley Fool
2 Newly Minted AI Stocks to Buy Right Now
Eli Lilly and Medtronic have recently joined the burgeoning field of AI stocks. 
Via The Motley Fool
3 Stocks Worth Buying at 52-Week Lows
Here are three stocks that are trading near their 52-week lows and may be primed for a short-term rally for opportunistic investors 
Via MarketBeat
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
From Pfizer Inc.
Via Business Wire
The 3 Best Healthcare Stocks to Buy for June 2023
There is an opportunity with these promising healthcare stocks for June 2023 while healthcare company stocks are in a price slump. 
Via InvestorPlace
The Top Healthcare Stocks to Buy With $100
There's plenty of upside in this multitrillion-dollar industry. 
Via The Motley Fool
Investing $43 in This Stock per Week for 5 Years Could Give You $500 in Annual Dividend Income
The risk of a dividend cut is minimal, and the yield of this stock is favorable. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.